Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CORVUS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

07/15/2021 | 04:09pm EDT

Item 2.02. Results of Operations and Financial Condition.


            On July 15, 2021, Corvus Pharmaceuticals, Inc. ("Corvus" or the

"Company") issued a press release regarding, among other matters, certain of its financial results for the second quarter of 2021. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.


            The information in this Item 2.02 of this Form 8-K and the Exhibit

99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



Item 8.01. Other Events.

           On July 15, 2021, the Company announced that it has discontinued its

Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations. The discontinuation is not related to any safety or efficacy issues observed in study patients. The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial. In particular, the Company announced that it is now enrolling an expansion cohort for HPV+ head and neck cancer and its goal is to present initial results from this cohort at a medical meeting later this year.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.      Description

  99.1                           Press release of Corvus Pharmaceuticals, Inc.
dated July 15, 2021.

104             Cover Page Interactive Data File (embedded within the Inline

XBRL document)

© Edgar Online, source Glimpses

All news about CORVUS PHARMACEUTICALS, INC.
09/22Health Care Stocks Follow Market Higher Wednesday
MT
09/22Health Care Stocks Edge Higher Premarket Wednesday
MT
09/22CORVUS PHARMACEUTICALS : Reports Results of Phase 3 Trial of Mupadolimab; Shares Fall Pre-..
MT
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology..
GL
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab
CI
09/17Top Premarket Gainers
MT
09/07Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GL
08/17CORVUS PHARMACEUTICALS : Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-1 i..
AQ
08/17CORVUS PHARMACEUTICALS' : Chinese Partner Gets Regulatory Nod to Conduct Early Stage Study..
MT
08/16CORVUS PHARMACEUTICALS' : Application for Phase 1 Clinical Trial Accepted by Chinese Regul..
MT
More news
Analyst Recommendations on CORVUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -40,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,08x
Yield 2021 -
Capitalization 288 M 288 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 8,45x
Nbr of Employees 42
Free-Float 88,4%
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | CRVS | US2210151005 | MarketScreener
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 6,80 $
Average target price 5,13 $
Spread / Average Target -24,6%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Mehrdad Mobasher Chief Medical Officer & Senior Vice President
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.91.01%288
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353